SonoTran® is designed to:
By enhancing the dose and distribution throughout solid tumour tissues.
By enhancing tumour dose whilst administering lower systemic dose to the patient.
|Enable New Delivery Routes & Indications
By overcoming pharmacokinetic-related limitations.
|Increase Therapeutic Consistency
By reducing variability associated with tumour delivery on a patient-to-patient basis.
|Extend Patent Life
By combining an off-patent therapeutic agent with patent protected SonoTran technology.
|Salvage Failed Therapeutic Agents
By enhancing efficacy at or below the maximum tolerated and/or maximum feasible dose.
|Reduce Cost of Goods
By reducing systemic dose, therapeutic agent manufacturing costs can be reduced.